Hot Features
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed ... Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.6787 | -19.9032258065 | 3.41 | 3.51 | 2.63 | 3326785 | 3.08541775 | CS |
| 4 | -0.2987 | -9.85808580858 | 3.03 | 3.94 | 2.41 | 3174649 | 3.18384925 | CS |
| 12 | 0.1513 | 5.86434108527 | 2.58 | 3.94 | 2.13 | 2006190 | 3.01842475 | CS |
| 26 | 0.2713 | 11.0284552846 | 2.46 | 3.94 | 1.66 | 1921349 | 2.58207109 | CS |
| 52 | 0.9313 | 51.7388888889 | 1.8 | 4.5372 | 1.66 | 2200439 | 2.76695986 | CS |
| 156 | -6.9387 | -71.7549120993 | 9.67 | 11.91 | 0.9101 | 2187051 | 4.26795472 | CS |
| 260 | -31.2487 | -91.9620364921 | 33.98 | 73.025 | 0.9101 | 2014430 | 10.55454562 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.